Learn about the potential side effects of iron protein succinylate. Includes common and rare side effects information for consumers and healthcare professionals. Name: Iron protein succinylate; Accession Number: DB; Type: Small Molecule; Groups: Approved, Investigational; Description: Not. View pharmacology details for the Iron protein succinylate generic medicine.

Author: Akinogul Feshicage
Country: Rwanda
Language: English (Spanish)
Genre: Marketing
Published (Last): 19 December 2007
Pages: 476
PDF File Size: 4.22 Mb
ePub File Size: 7.48 Mb
ISBN: 681-8-50514-874-1
Downloads: 7301
Price: Free* [*Free Regsitration Required]
Uploader: Arashizuru

Some of the brands for iron protein succinylate might be better known than iron succinyalte succinylate itself. Its efficacy and tolerability have been proved in about patients, enrolled in 3 multicenter clinical trials. Serum iron concentrations in these patients were no different from those obtained in 10 ‘normal’ hypochromic anaemic patients.

Search Our Scientific Publications & Authors

Five hundred and forty-nine patients received ITF ; patients were treated with ferrous sulphate. In this brief review the preclinical safety studies on iron protein succinylate synonym: If the pharmacy that’s willing to deliver medicines to your home doesn’t have iron protein succinylate in stock, you can ask for one of the branded alternatives for iron protein succinylate. This paper provides an overview of the pharmacokinetic and clinical data on Fe-ASP use.

P Cremonesi I Caramazza. The increase induced by iron protein succinylate was more prolonged than that of ferritin. The absorption of iron from iron succinyl-protein complexes was investigated in mice.

A child allergic to cow’s milk developed a mild systemic allergic reaction after the first dose of Ferplex 40 iron proteinsuccinylate. Sign In Join Now.

Iron protein succinylate Side Effects in Detail –

Allergy and Immunology Studying the gastrointestinal motor effects of iron compounds may help to elucidate the mechanism originating the gastrointestinal side effects of frequently reported during martial therapy. A second group of iron deficient patients with no anti H2 concurrent treatment were admitted prtein the same iron treatment, lasting 60 days.

Meta-analysis of efficacy and tolerability data on iron proteinsuccinylate in patients with iron deficiency anemia of different severity. Iron protein succinylate is a non-toxic therapeutic iron compound.


Pharmacol Toxicol Sep;87 3: Electronic databases – Medline, the Cochrane Library, and Embase were searched for studies published up to January sjccinylate J Clin Pharm Ther Apr 12;38 2: Iron protein succinylate is a generic medicine succinjlate and there are several brands available for it.

A product containing a high amount of iron and maintaining all the necessary characteristics of stability and solubility for a protien can be prepared by succinylating the proteins, in the specific case the milk proteins, before the reaction with the iron salt. The efficacy of simethicone available in liquid form as Mylicon Drops in the treatment of infant colic was assessed in 51 healthy infants between 2 and 12 weeks of age.

Clinical or observational studies reporting data on the tolerability of oral iron supplements were included.

Clin Drug Investig ;25 S Scremin L Caprioglio. To evaluate whether folate supplementation to iron is able to accelerate solving of iron deficiency anaemia in pregnancy. Iron protein succinylate is an iron-protein complex, in which iron is present in ferric form. Effect of iron succinyl-protein complexes on gastrointestinal motility in the fasting dog.

Involvement of iron ferric reduction in the iron absorption mechanism of a trivalent iron-protein complex iron protein succinylate. Both treatments lasted 60 days. It has been developed for oral iron-supplementation therapy and is characterized by a very favorable tolerability profile. Inclusion criteria were iron-deficiency type of anemia, and hemoglobin levels below of Pediatr Allergy Immunol May;17 3: Electrophoresis indicates that the iron succinyl protein is homogeneous and gel filtration shows an apparent high molecular weight that contributes to the stability of the complexed iron.

In 6 fasting, conscious dogs, fitted with 8 bipolar electrodes and 3 strain-gauge force transducers along the gastrointestinal tract, gastrointestinal motor activity was recorded. The overall clinical rating was significantly in favor of ITFwith The effects of iron protein succinylate ITFan iron complex insoluble under acid conditions, and ferrous sulfate were studied in the rat.

These observations confirm that, although the most modern preparations of ferrous sulphate exhibit a relatively low frequency of adverse events of limited clinical concern, it is nevertheless possible to decrease both the prevalence and the duration of such events without prejudice for the clinical efficacy, with the use of more “physiological” preparations in which the iron is reversibly bound to a protein carrier, thus effectively removing one of the main obstacles to the pritein compliance with treatments that must be administered for prolonged periods of time.


Dietary iron deficiency in the rat. Iron proteinsuccinylate ITFCAS is an iron derivative for the oral treatment of iron deficiency anemia. The aim of this study was to evaluate the efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy. A prospective, controlled, double-blind, double-dummy, multicenter clinical trial was made to assess the efficacy and tolerability of iron-protein-succinylate ITF in sucicnylate with a well known iron preparation in the treatment of iron deficiency or iron deficient anemia.

The serum iron increase induced by ITF is delayed when compared with ferrous sulphate. Clin Ther ;10 4: Clin Exp Obstet Gynecol ;38 2: The absorption of iron after oral administration of 80 mg iron–protein–succinylate complex was evaluated by determining serum iron concentrations in 10 patients who had undergone total gastrectomy more than 1 year before and were suffering from hypochromic anaemia.

Succimylate dividing the patient population according to pathological conditions iron deficiency sudcinylate overt anemiaor according to the etiopathogenesis of the iron deficiency increased requirement, or increased loss in adults and in the elderlyseparate analyses on the treatment outcome were made and have been included. Tolerability of different oral succihylate supplements: Aim of this multicentric clinical trial was to evaluate the efficacy and tolerability of a new iron compound: Obstetrics and Gynecology